Skip to main content
. Author manuscript; available in PMC: 2008 Nov 25.
Published in final edited form as: Oncogene. 2007 Apr 16;26(43):6280–6288. doi: 10.1038/sj.onc.1210456

Figure 1. Aberrant centriole configuration following treatment with the proteasome inhibitor Z-L3VS.

Figure 1

(A) Fluorescence microscopic analysis of U-2 OS cells stably expressing centrin-GFP to visualize centrioles (arrows; inserts) after either treatment with 0.1% DMSO (top panels) or 1 μM Z-L3VS (bottom panels) for 48 h. Nuclei stained with DAPI. Scale bar indicates 10 μm.

(B) Quantification of U-2 OS/centrin-GFP cells with more than one daughter centriole per maternal centriole after treatment with either 0.1% DMSO or 1 μM Z-L3VS for 48 h. Each bar represents mean and standard error of at least three independent experiments with a minimum of 100 cells counted per experiment.